TABLE 2.
Multivariate a Cox proportional hazards regression of graft failure in DCD recipients (N = 2901), 2016–2020
| Variables | HR (95% CI) | p value |
|---|---|---|
| Donor | ||
| HTK (reference UW) | 0.73 (0.55–0.98) | 0.037 |
| Age | 1.01 (1.00–1.02) | 0.018 |
| ECD | 1.41 (0.89–2.21) | 0.140 |
| fDWIT | 1.02 (1.01–1.04) | 0.005 |
| White race | 0.93 (0.71–1.21) | 0.577 |
| Male sex | 0.92 (0.72–1.18) | 0.514 |
| CIT | 1.06 (0.99–1.13) | 0.072 |
| Recipient | ||
| Age | 1.01 (0.99–1.02) | 0.601 |
| Male sex | 1.31 (1.01–1.70) | 0.045 |
| White race | 0.79 (0.60–1.03) | 0.084 |
| Diabetes mellitus | 1.16 (0.91–1.47) | 0.226 |
| BMI | 1.00 (0.99–1.03) | 0.575 |
| MELD score | 1.01 (0.99–1.02) | 0.467 |
| Pretransplant life support requirement | 2.13 (1.18–3.82) | 0.011 |
| Ascites (mild or worse) | 1.20 (0.89–1.61) | 0.240 |
| HCC | 1.24 (0.93–1.64) | 0.133 |
| SLKT | 0.95 (0.63–1.45) | 0.826 |
| Diagnosis | 0.96 (0.88–1.04) | 0.325 |
Diagnosis were the six UNOS categories for liver disease (Noncholestatic cirrhosis, Cholestatic liver diseases, Biliary atresia, Acute hepatic failure, Metabolic diseases, and Malignant neoplasms or benign tumors) – there were no overall differences in the categories of liver disease between the two groups.
Abbreviations: BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; DCD, donation after circulatory death; ECD, expanded criteria donor; fDWIT, functional donor warm ischemia time; HCC, hepatocellular carcinoma; HR, hazard ratio; HTK, histidine‐tryptophan‐ketoglutarate solution; MELD, Model for End‐Stage Liver Disease; SLK, simultaneous liver–kidney transplantation; UW, University of Wisconsin solution.
Individual transplant centers were included as a random effect (θ = 0.091, likelihood ratio test of θ = 0: p = 0.006) in a shared frailty model. Of the fWDIT data, 14% was missing and was ignored in this analysis.